INDP News and Press, Indaptus Therapeutics Inc. From 11/07/23

Indaptus Therapeutics Inc. (INDP) is expected to report $-0.55 for Q3 2023

2023-11-06 18:05:39 ET More on Indaptus Therapeutics Seeking Alpha’s Quant Rating on Indaptus Therapeutics Historical earnings data for Indaptus Therapeutics Financial information for Indaptus Therapeutics For further details see: Indaptus Therapeu...

NEW YORK, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”) today announced financial results for the third quarter ended September 30, 2023 and provided a corporate update. “We continue to be encour...

NEW YORK, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical biopharma company that utilizes a proprietary killed, non-pathogenic bacteria-based platform to generate a stabilized package of immune agonists to activate both innate (immediate) and adaptive (lea...

Poster to be presented at 38 th Annual Meeting of the Society for Immunotherapy of Cancer on November 4 , 2023 NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) announces it will be presenting interim data from the first cohort of f...

NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced today that Jeffrey A. Meckler, Chief Executive Officer, will present a corporate overview at the LD Micro Main Event XVI. The conference is being held on October 3 – 5, 2023 at the Luxe Sunset...

NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ: INDP) announces that Indaptus’ CEO, Jeffrey Meckler will present at Tribe Public’s Webinar Presentation and Q&A Event titled “ Immunotherapy Reimagined." The Event is scheduled to begin ...

NEW YORK, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”) announces dosing of the first patient in the second cohort of patients to receive a single dose of Decoy20 in the INDP-D101 trial. This cohort dose is ...

NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced today that Jeffrey A. Meckler, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 25 th Annual Global Investment Conference. The conference is being held on Septemb...

2023-08-14 09:07:38 ET Indaptus Therapeutics press release ( NASDAQ: INDP ): Q2 GAAP EPS of -$0.39. As of June 30, 2023, the Company had cash, cash equivalents and marketable securities of approximately $19.7 million as compared to $26.4 million as of December 31, 2022. ...